Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07YGH
|
||||
| Former ID |
DCL000374
|
||||
| Drug Name |
GSK239512
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Mild to moderate alzheimer disease; Dementia [ICD9: 290-294, 331.0; ICD10:F01-F07, G30] | Phase 2 | [1] | ||
| Company |
GSK
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H27N3O2
|
||||
| Canonical SMILES |
C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O
|
||||
| InChI |
1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
|
||||
| InChIKey |
YFRBKEVUUCQYOW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01772199) Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.